CN101981033B - 用作激酶抑制剂的取代的咪唑并哒嗪化合物 - Google Patents

用作激酶抑制剂的取代的咪唑并哒嗪化合物 Download PDF

Info

Publication number
CN101981033B
CN101981033B CN200980111092.8A CN200980111092A CN101981033B CN 101981033 B CN101981033 B CN 101981033B CN 200980111092 A CN200980111092 A CN 200980111092A CN 101981033 B CN101981033 B CN 101981033B
Authority
CN
China
Prior art keywords
amino
pyridazine
imidazo
trans
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980111092.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101981033A (zh
Inventor
布赖恩·E·芬克
陈利冰
陈平
达姆帕尔·S·多德
阿什维尼库马·V·加韦
金崇薰
韦恩·瓦卡罗
张丽台
赵玉芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101981033A publication Critical patent/CN101981033A/zh
Application granted granted Critical
Publication of CN101981033B publication Critical patent/CN101981033B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200980111092.8A 2008-02-06 2009-02-06 用作激酶抑制剂的取代的咪唑并哒嗪化合物 Expired - Fee Related CN101981033B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2665108P 2008-02-06 2008-02-06
US61/026,651 2008-02-06
PCT/US2009/033455 WO2009100375A1 (en) 2008-02-06 2009-02-06 Substituted imidazopyridazines useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101981033A CN101981033A (zh) 2011-02-23
CN101981033B true CN101981033B (zh) 2015-02-04

Family

ID=40566064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980111092.8A Expired - Fee Related CN101981033B (zh) 2008-02-06 2009-02-06 用作激酶抑制剂的取代的咪唑并哒嗪化合物

Country Status (5)

Country Link
US (1) US8389527B2 (https=)
EP (1) EP2240488B1 (https=)
JP (1) JP5394404B2 (https=)
CN (1) CN101981033B (https=)
WO (1) WO2009100375A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
TW201107330A (en) * 2009-07-31 2011-03-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
JP5802676B2 (ja) * 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2011078221A1 (ja) 2009-12-24 2011-06-30 味の素株式会社 イミダゾピリダジン化合物
EP2563792B1 (en) 2010-04-28 2014-08-27 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
DE102011075398A1 (de) * 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
JP6073343B2 (ja) * 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9475817B2 (en) * 2012-12-21 2016-10-25 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
US20160199372A1 (en) * 2013-08-20 2016-07-14 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US9956220B2 (en) * 2014-06-19 2018-05-01 Bristol-Myers Squibb Company Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US10155765B2 (en) * 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
HRP20241768T1 (hr) * 2016-08-10 2025-02-28 Takeda Pharmaceutical Company Limited Heterociklički spoj
ES2902995T3 (es) 2016-10-07 2022-03-30 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
EP3541817B1 (en) * 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
LT3568396T (lt) * 2017-01-11 2021-02-10 Leo Pharma A/S Nauji amino-imidazopiridino dariniai, kaip janus kinazės inhibitoriai ir jų farmacinis panaudojimas
CN113348021B (zh) * 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
US12473290B2 (en) * 2019-03-05 2025-11-18 Bristol Myers-Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
WO2022156657A1 (en) * 2021-01-19 2022-07-28 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076458A1 (en) * 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
WO2007038314A2 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016192A2 (en) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
US20080045536A1 (en) * 2005-09-22 2008-02-21 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH635587A5 (fr) 1978-01-09 1983-04-15 Aron Sa Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3446812A1 (de) 1984-12-21 1986-06-26 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
CA1273336A (en) 1986-04-25 1990-08-28 Chi-Ping Tseng Herbicidal heterocyclic carbonyl sulfonamides
FR2619818B1 (fr) 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
JPH07101958A (ja) 1992-10-16 1995-04-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
JPH07133280A (ja) 1993-11-09 1995-05-23 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
EP1345941A1 (fr) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
DE60301339T2 (de) 2002-03-07 2006-03-09 Smithkline Beecham Corp. Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
TW200504073A (en) 2003-04-17 2005-02-01 Basf Ag Bicyclic compounds and their use for controlling harmful fungi
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
WO2006016715A1 (ja) 2004-08-13 2006-02-16 Teijin Pharma Limited ピラゾロ［１，５－ａ］ピリミジン誘導体
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
CN101142219A (zh) 2005-03-17 2008-03-12 帝人制药株式会社 吡唑并嘧啶衍生物或其医学上容许的盐
EP1869049B1 (en) 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
WO2006099972A1 (en) 2005-03-23 2006-09-28 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076458A1 (en) * 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
WO2007038314A2 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20080045536A1 (en) * 2005-09-22 2008-02-21 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016192A2 (en) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhe Nie et al..Structure-based design,synthesis,and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.《Bioorganic & Medicinal Chemistry Letters》.2007,第17卷(第15期),4191-4195. *

Also Published As

Publication number Publication date
JP5394404B2 (ja) 2014-01-22
EP2240488B1 (en) 2016-11-02
CN101981033A (zh) 2011-02-23
JP2011511095A (ja) 2011-04-07
EP2240488A1 (en) 2010-10-20
US20100323994A1 (en) 2010-12-23
US8389527B2 (en) 2013-03-05
WO2009100375A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
CN101981033B (zh) 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CN102325752B (zh) 咔唑和咔啉激酶抑制剂
CN101687874B (zh) 吡咯并三嗪激酶抑制剂
CN102245609B (zh) 可用作激酶抑制剂的咪唑并哒嗪甲腈
CN101594871B (zh) 吡咯并嘧啶化合物及其用途
US8445676B2 (en) Pyrrolotriazine kinase inhibitors
CN101228161B (zh) 适用作蛋白激酶抑制剂的吡咯并吡啶类
KR101392678B1 (ko) 피롤로트리아진 키나제 억제제
CN103261167B (zh) 取代的6，6-稠合含氮杂环化合物及其用途
US7531539B2 (en) Pyrrolotriazine kinase inhibitors
CN102918045A (zh) 作为蛋白激酶抑制剂的取代的吡咯并三嗪
CN101652363B (zh) 用作激酶抑制剂的噻唑基化合物
CN102471339A (zh) 激酶的吡咯并吡啶抑制剂
WO2008021859A1 (en) Pyrrolotriazine kinase inhibitors
CN102232076A (zh) 吡咯并吡嗪基脲激酶抑制剂
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN101679406A (zh) 用作激酶抑制剂的噻唑基化合物
CN106661056A (zh) 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物
CN107922407A (zh) 呼吸道合胞病毒抑制剂
JP2011513419A (ja) ピロロトリアジンキナーゼ阻害剤
CN101627027A (zh) 氨基吡唑激酶抑制剂
WO2022063050A1 (zh) 吡唑类化合物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150204

Termination date: 20220206